Kelly E Dooley

Author PubWeight™ 10.93^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	TMC207: the first compound of a new class of potent anti-tuberculosis drugs.	Future Microbiol	2010	2.28
2	Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.	Am J Respir Crit Care Med	2015	1.86
3	Fluoroquinolone resistance in patients with newly diagnosed tuberculosis.	Clin Infect Dis	2003	1.53
4	Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice.	PLoS Negl Trop Dis	2011	1.07
5	Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis.	Antimicrob Agents Chemother	2013	1.03
6	Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine.	Antimicrob Agents Chemother	2013	0.96
7	Treatment Failure, Drug Resistance, and CD4 T-Cell Count Decline Among Postpartum Women on Antiretroviral Therapy in South Africa.	J Acquir Immune Defic Syndr	2016	0.86
8	Pharmacokinetic Interactions for Drugs with a Long Half-Life—Evidence for the Need of Model-Based Analysis.	AAPS J	2016	0.84
9	Reply to Seddon, Schaaf, and Hesseling.	Clin Infect Dis	2012	0.75